Skip to content

The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN)

The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN) Across National University Health System (NUHS)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06062836
Acronym
PICMAN
Enrollment
120
Registered
2023-10-02
Start date
2022-04-01
Completion date
2024-04-30
Last updated
2023-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Syndrome

Brief summary

Background Changes in metabolism and mitochondrial function appear to precede cardiac dysfunction, with much evidence supporting metabolic dysregulation as one of the earliest precursors of cardiovascular disease. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) across National University Health System (NUHS) is a pilot, prospective, multi-ethnic cohort study in Singapore. Through extensive phenotyping in a preventive cardiology cohort, the central aim is to define the metabolic flexibility range in a cohort of individuals at elevated risk of atherosclerotic cardiovascular disease, to correlate metabolic flexibility to measures of cardiometabolic health, including diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease.

Detailed description

Aims 1. Define norms for metabolic flexibility in a multi-ethnic Southeast Asian cohort of individuals without manifest ASCVD 2. Understand the association of metabolic inflexibility with cardiovascular measures of diastolic dysfunction and coronary and cerebral atherosclerosis 3. Understand the association of metabolic inflexibility with measures of body fat distribution 4. Understand the correlation between metabolic flexibility and insulin sensitivity along the spectrum of subclinical cardiovascular disease and severity of non-alcoholic fatty liver disease 5. Associations of the gut microbiome as well as metabolomic and molecular markers with cardio-cerebrovascular measures, metabolic flexibility and liver fibrosis The PICMAN study seeks to lay the foundations for further future larger scale and more experimentally ambitious studies based on the overarching hypothesis that metabolic flexibility is an early marker in subclinical cardiovascular disease, indicating a point of timely intervention where the disease process is still reversible. The importance of a deeply-phenotyped local cohort will allow us to study the progression of CVD in seemingly well adults, converging imaging, biochemical, metabolic markers, and 'omics analysis.

Interventions

None listed

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 21-70 at screening * 10-year ASCVD risk \> 5% measured by QRISK 3 calculator

Exclusion criteria

* Established DM (Prior diagnosis, long term medications or HbA1c \>=6.5) * Established CVD, such as ischemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation * Pregnancy * Known contraindications to CT scan, such as allergy to contrast

Design outcomes

Primary

MeasureTime frameDescription
Metabolic flexibilityUp to 5 yearsMetabolic flexibility will be calculated (deltaRQ)

Countries

Singapore

Contacts

Primary ContactMayank Dalakoti
mayank_dalakoti@nuhs.edu.sg+6566011036
Backup ContactRoger Foo
roger.foo@nus.edu.sg+6566011036

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026